studies on tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ECO 2026: tirzepatide shows potential

Weekly dosing creates a predictable, sustained effect on appetite signals in the brain and slows gastric emptyingtwo mechanisms that drive weight loss

flavors, sweeteners: acesulfame K, sucralose

Samuel Rodriguez, a family physician specializing in aesthetic medicine and skin health at Montreals Dermapure Outremont and a member of the 65-clinic networks Medical Advisory Committee

However, this outcome was reported in a subset of trials and showed less consistent statistical significance in sensitivity analyses, suggesting potential benefits in cardiac function and disease progression

We will assess your progress and adjust the dosage as needed to guarantee optimal outcomes